Resumo

GRANDA-LOBATO, P; CORREA-PEREZ, A; SILVA-CUEVAS, M  e  GARCIA-LUQUE, A. Positive assessment of drugs: from April, May and June of 2022. Sanid. Mil. [online]. 2022, vol.78, n.3, pp.182-187.  Epub 30-Jan-2023. ISSN 1887-8571.  https://dx.doi.org/0.4321/s1887-857120220003000010.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from April to June of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Asciminib (Scemblix®); Budesonide (Kinpeygo®); Capmatinib (Travecta®); Efgartigimod Alfa (Vyvgart®); Eladocagene Exuparvovec (Upstaza®); Eptacog Beta Activated (Cevenfacta®); Birch Bark Extract (Fisulvez®); Lasmiditan (Rayvow®); Lenacapavir (Sunlenca®); Melphalan Flufenamide (Pepaxti®); Mosunetuzumab (Lunsumio®); Olipudase Alfa (Xenpozyme®); Lonafarnib (Zokinvy®); COVID-19 vaccine (inactivated, adjuvanted, adsorbed) (Valneva®); Valoctocogene Roxaparvovec (Roctavian®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )